Results
74,179 records
Include
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 7 | Sibold William JohnDirector, President and CEO |  MDGLMADRIGAL PHARMACEUTICALS, INC.Open-market sale · 10b5-1 plan | SELL | $558K 1,040 sh |
Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramEvery ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $558K 1,040 sh |
| Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $280K 520 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $344K 640 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $273K 505 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $277K 522 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 6 | Feeley KevinCHIEF FINANCIAL OFFICER |  WGSGeneDx Holdings Corp.Option exercise | M | — 2,462 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 5 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER |  LTHLife Time Group Holdings, Inc.Option exercise | M | — 60.7K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Gracey CraigChief Accounting Officer |  OMDAOmada Health, Inc.Open-market sale · 10b5-1 plan | SELL | $14K 644 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 5 | Malady KyleEVP and Group CEO-VZ Business |  VZVERIZON COMMUNICATIONS INCGrant or award | A | $1,738 122 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 5 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER | LTHLife Time Group Holdings, Inc. Option exercise | M | — 59.4K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Mercier JohannaChief Comm & Corp Aff Officer |  GILDGILEAD SCIENCES, INC.Option exercise | M | — 2,797 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 5 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER | LTHLife Time Group Holdings, Inc. Option exercise | M | — 34.8K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | O'Day Daniel PatrickDirector, Chairman & CEO | GILDGILEAD SCIENCES, INC. Option exercise | M | — 8,780 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 5 | Rogers George Ted IIIDirector |  GREEVulcan Infrastructure & Power Inc.Derivative conversion | C | — 16.0K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER | WGSGeneDx Holdings Corp. Option exercise | M | — 6,547 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 5 | Rogers George Ted IIIDirector | GREEVulcan Infrastructure & Power Inc. Derivative conversion | C | — 16.0K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $184K 347 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $196K 368 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $69K 131 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $212K 396 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $87K 160 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner |  HNGEHinge Health, Inc.Derivative conversion · 10b5-1 plan | C | — 150.0K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 4 | Tsao DavidDirector, Chief Technology Officer |  BLLNBillionToOne, Inc.Option exercise · 10b5-1 plan | M | $28K 10.0K sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $196K 362 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $415K 761 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Tsao DavidDirector, Chief Technology Officer | BLLNBillionToOne, Inc. Option exercise · 10b5-1 plan | M | $28K 10.0K sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $652K 1,202 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $116K 215 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $837K 1,539 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $371K 687 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner | HNGEHinge Health, Inc. Derivative conversion · 10b5-1 plan | C | — 150.0K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 3 | Brosius MarkEVP & Chief Mfg and Supply Cha |  ISRGINTUITIVE SURGICAL INCOpen-market sale · 10b5-1 plan | SELL | $7,996 23 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 3 | Tak Paul PeterDirector, Chief Executive Officer |  CADLCandel Therapeutics, Inc.Option exercise · 10b5-1 plan | M | — 125.0K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 3 | Brosius MarkEVP & Chief Mfg and Supply Cha | ISRGINTUITIVE SURGICAL INC Open-market sale · 10b5-1 plan | SELL | $9,145 25 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 3 | Sullivan Christopher RyanChief Financial Officer |  AVTXAvalo Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $82K 10.2K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $66K 120 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $86K 160 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $117K 218 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 1 | Arora TarunChief Accounting Officer |  RNGRingCentral, Inc.Open-market sale · 10b5-1 plan | SELL | $190K 2,679 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $57K 106 sh | Sep 11, 2026 traded Sep 11, 2026 |